Depemokimab is comparable in efficacy and safety to all other severe asthma biologics, with advantage of 6-month dosing 10/27/2026 Asthma +
Biologics for severe CRSwNP: dupilumab still leads in a network meta-analysis of 7 agents 10/26/2026 Chronis Sinusitis +
From CD20 to CD19: Deeper B-Cell Depletion in Autoimmune Disease 10/24/2026 Secondary immunodeficiency +
Signs of fatal perioperative anaphylaxis: pale and bradycardic 10/23/2026 Anaphylaxis Perioperative +
New targets in allergy: Siglec-6, SMURF2, IgE class-switch, KIT+ ILC2, SPRR2A-CSTA 10/22/2026 Immunology +
Anaphylaxis: "No response after two IM or nasal Epi doses — prepare to infuse Epi" 10/22/2026 Anaphylaxis +
Genetic testing in immunology: the right test for the right question 10/21/2026 IEE Immunodeficiency PIDD +
SCIT vs SLIT have similar clinical benefit via partially nonoverlapping pathways 9/12/2026 SCIT SLIT +
Beyond Weight Loss: Could Popular GLP-1 Drugs Like Ozempic Help Keep Asthma Attacks at Bay? 3/25/2026 Asthma +
Under-the-Tongue Treatment for Food Allergy: New Peanut Allergy Tablet Proves Safe in Early Trial Results 3/22/2026
A Game-Changer for Multi-Food Allergies? Omalizumab Matches Oral Immunotherapy's Long-Term Success - With Far Less Hassle 3/21/2026 Food Allergy Omalizumab +
Biologics vs. JAK Inhibitors for Atopic Dermatitis: Which One Wins for Your Patient? A 2026 Practical Guide 3/08/2026 Atopic Dermatitis Biologics Dupilumab JAK inhibitors +
2025: A Breakthrough Year for Chronic Urticaria - New FDA Approvals Reshaped Treatment 3/07/2026 Dupilumab Remibrutinib Urticaria +
Revolutionizing Respiratory Care: How Type 2 Biologics Are Changing the Game for Severe Asthma and Beyond 3/06/2026